Did longer AI-assisted Parkinson’s rehab improve movement?
No clear motor advantage emerged between one, two and three months of home training. The peer-reviewed Chinese trial randomized 120 people, analysed 71 and had no usual-care group, so its exploratory cognitive signal cannot establish benefit.
Editorial responsibility: The Impact of AI Editorial Desk · Report a factual concern
At a glance
- 1The trial randomized 120 people with early-stage Parkinson’s disease equally to one, two or three months of home training, scheduled for 15–30 minutes on five days each week.
- 2Only 71 participants entered the final analysis, and the groups did not differ significantly on the primary three-month motor outcome.
- 3A cognitive responder signal favoured three months over one month only in a post-hoc analysis; with no usual-care group and high attrition, it is hypothesis-generating rather than proof of benefit.
Research topic
Whether one, two or three months of AI-assisted home telerehabilitation produces different motor, cognitive, gait, daily-living or safety outcomes in people with early-stage Parkinson’s disease
The answer is no clear motor advantage
Longer exposure to the AI-assisted home programme did not produce a statistically significant advantage on the trial’s primary motor measure at three months. That is the central finding. The study compared different durations of the same rehabilitation approach, not AI-assisted rehabilitation against usual care, in-person physiotherapy or no exercise. It therefore cannot show whether the system itself improved movement; it can only ask whether continuing it for longer separated the three assigned groups.
The negative primary result matters because duration is a practical decision for patients, clinicians and health systems. A three-month digital programme demands more sustained effort, supervision and technical access than a one-month programme. This trial does not provide evidence that the longer commitment yields greater motor improvement. Its exploratory cognitive finding is interesting, but the paper itself says the result does not permit causal inference and needs a larger, prespecified test.[1]
Three groups changed duration, not the technology
Researchers at five Chinese centres enrolled people with early-stage Parkinson’s disease, defined as Hoehn–Yahr stage 2.5 or lower, and randomized 120 participants in a 1:1:1 ratio. The short, medium and long groups were assigned one, two or three months of training. Sessions were scheduled for 15 to 30 minutes, five days a week. Raters assessing outcomes were blinded to allocation, which reduces one important source of measurement bias even though participants necessarily knew how long they trained.
The system facilitated remote exercise rather than making a diagnosis or replacing a clinician. The published abstract does not support interpreting the algorithm as an autonomous treatment. A useful deployment question is therefore whether its exercise selection, movement feedback and remote monitoring add value beyond a comparable non-AI home programme. Because every arm received the AI-facilitated approach and only duration varied, this study cannot isolate that contribution.[1]
The denominator fell from 120 randomized to 71 analysed
Final analysis included 71 of the 120 randomized participants—about 59%. Losing 49 people after allocation is not a minor detail. Attrition reduces statistical power and can upset the balance produced by randomization if the people who remain differ from those who leave. The abstract describes attrition as high, so the absence of a significant difference should not be read as proof that duration never matters; the trial may have been unable to detect a modest effect.
For people considering home rehabilitation, retention is also an outcome in its own right. A digital exercise programme that works only for those who persist may have limited population benefit. Future reports should make clear why participants withdrew, whether dropout differed by group, how much assigned training was actually completed and whether analyses that include all randomized participants lead to the same conclusion.[1]
Motor function was primary; cognition was exploratory
The prespecified primary outcome was change from baseline to three months on Part III of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale, a clinician-rated measure of motor signs. Secondary outcomes covered cognition, mood, gait, activities of daily living and safety. The primary comparison was negative: the paper reports no significant between-group difference in motor change at three months.
A post-hoc responder analysis found a higher proportion of cognitive responders in the three-month group than in the one-month group. Post-hoc thresholds are selected after the main analysis and are more vulnerable to chance findings, especially when many outcomes are examined. Weak correlations between changes in cognition and motor parameters did not remain statistically significant after false-discovery-rate correction. The responsible conclusion is not that longer AI rehabilitation improves cognition, but that the pattern may justify a specifically designed trial.[1]
No recorded harm is reassuring but not conclusive
The researchers recorded no falls or adverse events during the trial. That is reassuring for the participants who completed the observed programme. It does not establish safety for everyone with Parkinson’s disease: the sample was limited to early-stage disease, the final denominator was 71, and people unable or unwilling to continue may have different risks from completers.
Safe scaling would need screening for mobility, cognition, vision, hearing, home hazards and digital access, alongside a clear route to a human clinician when the system detects difficulty or when symptoms change. Absence of recorded events in a small exploratory trial should support further evaluation, not removal of clinical safeguards.[1]
What would change the assessment
Confidence would rise with a larger trial that compares a fixed AI-assisted programme with usual care, a matched non-AI digital exercise programme and, where feasible, therapist-led rehabilitation. Allocation, primary outcomes, cognitive responder thresholds and missing-data handling should be fixed in advance. An intention-to-treat analysis should preserve every randomized participant, while adherence and reasons for withdrawal should be reported by arm.
The most useful outcomes extend beyond short rating-scale changes: falls, participation in daily life, caregiver burden, access, technical failures, quality of life and durability after training stops. Independent replication outside the five Chinese centres would show whether language, housing, clinical pathways and internet access alter performance. Until then, the study supports feasibility and further research, not a claim that a longer AI-assisted course improves movement or cognition.[1]
What this means for people
- People with Parkinson’s should not infer that three months of this system improves movement more than a shorter course.
- Home rehabilitation may reduce travel barriers, but only if interfaces, support and safety procedures work for people who are most likely to drop out.
- Clinicians still need to individualize exercise, review changing symptoms and offer non-digital alternatives.
Global context
The trial was conducted across five centres in China and funded through Chinese national hospital research awards. Home layout, rehabilitation staffing, broadband access, language and clinical follow-up differ internationally. A duration comparison in early-stage disease is therefore not a universal deployment result; local health systems need controlled evidence against their own usual care and inclusion of people with limited digital access.
What the evidence does not yet show
- The primary motor comparison was negative.
- Only 71 of 120 randomized participants were included in the final analysis, creating substantial uncertainty from attrition and reduced power.
- There was no usual-care, non-AI digital or in-person comparison group, so the study cannot isolate the effect of the AI component.
- The cognitive responder difference was post hoc and exploratory, while related correlations did not survive correction for multiple testing.
- The sample covered early-stage Parkinson’s disease at five Chinese centres and does not establish safety or effectiveness for broader populations.
What to watch next
- A larger preregistered trial with intention-to-treat analysis and lower attrition.
- Direct comparison with usual care and a matched non-AI home exercise programme.
- Prespecified cognitive outcomes rather than post-hoc responder thresholds.
- Reporting of adherence, withdrawal reasons, falls, daily participation and longer-term durability.
Living evidence record
Impact record IAI-0T4OKGX
Evidence stage
Studied
Confidence
Supported
Reporting basis
Source analysis
Independent or research support
Present
Record status
Monitoring
Last checked
7 October 2026
Source trail
1 direct source across 1 source type.
People impact
Documented in this record.
Uncertainty
Limits and next checks are explicit.
Stages describe the evidence available—not whether a technology is good or bad. See the public method.
Single-source reporting disclosure
This record analyses one direct source. It can establish what npj Digital Medicine published or reported, but it is not independent corroboration of every performance claim or predicted outcome. The confidence label will change only when broader evidence is added.
Evidence trail
Sources used for this report
Links checked 7 October 2026
This report is labelled source analysis. We summarise and analyse source material in our own words; company statements remain attributed claims until independently supported. Translated summaries preserve the meaning of the original source and link back to it. Read our editorial standards.
Continue the story
Related reporting
Health & Life Sciences
Can AI estimate survival after a Parkinson’s diagnosis?
A peer-reviewed Chinese registry study compared four survival models in 3,148 people with Parkinson’s disease. A transparent Cox model matched the machine-learning alternatives, but validation stayed within the same registry and no clinical-impact study was performed.
9 min · 2 sources
Health & Life Sciences
Can AI discover new MRI signs for glioblastoma?
It generated eight candidate visual signs from 106 glioblastoma scans, but only one was externally tested. Two radiologists achieved moderate discrimination between 50 glioblastomas and 50 metastases, so this is a discovery signal—not a clinical diagnostic.
7 min · 1 source
Health & Life Sciences
Can multi-agent AI improve clinical notes without inventing facts?
In a blinded test of 30 resident-written hyperthyroidism notes, the specialist system raised median documentation scores from 39 to 42, cut positive factual hallucinations to 6.67% versus 26.67% for a general model and saved 112.9 seconds of physician editing per note. The scope is narrow and human review remains essential.
6 min · 1 source
The Impact Brief
Keep the evidence trail, not the noise.
Get the most consequential AI developments with direct sources and clear limits.
Reader commentary
Add evidence, experience or a question
No account is required. Reader notes are published after a brief civility, relevance and safety check; disagreement is welcome.
Explore commentary across the portal →Published reader notes
0No published reader notes yet. You can start the evidence-led discussion above.
Prefer a private correction or response? Contact the newsroom.